Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF.
暂无分享,去创建一个
[1] L. To,et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF , 1998, Bone Marrow Transplantation.
[2] H. Goldschmidt,et al. Recombinant human granulocyte and granulocyte–macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells , 1998, Bone Marrow Transplantation.
[3] D. Catovsky,et al. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue , 1998, Bone Marrow Transplantation.
[4] A. Weaver,et al. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy , 1998, Bone Marrow Transplantation.
[5] G. Gleim,et al. CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Barlogie,et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Kröger,et al. Schedule-dependency of granulocyte colony-stimulating factor in peripheral blood progenitor cell mobilization in breast cancer patients. , 1998, Blood.
[8] B. McAneny,et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.
[9] D. Linch,et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration , 1998, Bone Marrow Transplantation.
[10] A. Palumbo,et al. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high‐dose chemotherapy courses , 1997, British journal of haematology.
[11] M. Aapro,et al. A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. , 1997, European journal of cancer.
[12] J. Hainsworth,et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte‐colony‐ stimulating factor: an analysis of 497 patients , 1997, Transfusion.
[13] D. Linch,et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non‐glycosylated G‐CSF in healthy volunteers , 1997, British journal of haematology.
[14] R. Arranz,et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone , 1997, Bone Marrow Transplantation.
[15] R. Fanin,et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. , 1997, Blood.
[16] C. Scott,et al. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. , 1997, Blood.
[17] R. Storb,et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Copelan,et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Ortuño,et al. Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG‐CSF for Mobilizing Peripheral Blood Progenitor Cells , 1997, British journal of haematology.
[20] I. Tabbara,et al. The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation. , 1997, Cancer investigation.
[21] T. Springer,et al. Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Howell,et al. Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] N. Ferrara,et al. Vascular endothelial growth factor. , 1996, European journal of cancer.
[24] D. Crowther,et al. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. , 1996, Blood.
[25] G. Koumakis,et al. Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in patients with lymphoma, myeloma and solid tumors , 1996, European journal of haematology.
[26] K. J. Nielsen,et al. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. , 1996, Journal of hematotherapy.
[27] P. Pedrazzoli,et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. , 1996, Anticancer research.
[28] H. Goldschmidt,et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. , 1996, Bone marrow transplantation.
[29] S. Rodenhuis,et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] N. Kröger,et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. , 1996, Bone marrow transplantation.
[31] T. Nakahata,et al. Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG‐CSF) in normal volunteers: dose–effect relationship for filgrastim with the character of mobilized PBPC , 1996, British journal of haematology.
[32] N. Schmitz,et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.
[33] G. Bonadonna,et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] K. Takenaka,et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. , 1996, Journal of hematotherapy.
[35] R. Bataille,et al. G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma , 1996, British journal of haematology.
[36] J. Winter,et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Roberts,et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.
[38] R. Möhle,et al. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. , 1995, Experimental hematology.
[39] C. Craddock,et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[40] Janet Rossant,et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.
[41] C. Begley,et al. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] M. Vadas,et al. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins , 1995, The Journal of experimental medicine.
[43] L. Terstappen,et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. , 1995, Blood.
[44] L. To,et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. , 1994, Blood.
[45] A. Nademanee,et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Asano,et al. A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers. , 1994, Experimental hematology.
[47] C. Nissen,et al. In Vitro Comparison of the Biological Potency of Glycosylated versus Nonglycosylated rG-CSF , 1994 .
[48] J. Armitage,et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. , 1994, Blood.
[49] T. Papayannopoulou,et al. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Strippoli,et al. Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s) , 1993, Stem cells.
[51] H. Goldschmidt,et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. , 1993, Experimental hematology.
[52] G. Rosner,et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.
[53] P. Mauch,et al. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. , 1993, Blood.
[54] H. Goldschmidt,et al. Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease--the role of haematopoietic growth factors. , 1993, Bone marrow transplantation.
[55] C. Begley,et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. , 1992, British Journal of Cancer.
[56] L. To,et al. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. , 1992, Bone marrow transplantation.
[57] G. Demetri,et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. , 1992, Blood.
[58] G. Fritsch,et al. Report on the European Workshop on Peripheral Blood Stem Cell Determination and Standardization--Mulhouse, France, February 6-8 and 14-15, 1992. , 1992, Journal of hematotherapy.
[59] L. Schwartzberg,et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. , 1992, Journal of hematotherapy.
[60] L. To,et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. , 1990, Experimental hematology.
[61] A. Ho,et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Experimental hematology.
[62] J. Villeval,et al. Effect of recombinant human granulocyte‐macrophage colony stimulating factor on progenitor cells in patients with advanced malignancies , 1990, British journal of haematology.
[63] F. Herrmann,et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. , 1989, Blood.
[64] A. Pileri,et al. GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION , 1989, The Lancet.
[65] W. Piacibello,et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. , 1989, The Journal of clinical investigation.
[66] L. To,et al. The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia. , 1989, Bone marrow transplantation.
[67] J. Villeval,et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.
[68] D. Crowther,et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. , 1988, British Journal of Cancer.
[69] M. Socinski,et al. GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN , 1988, The Lancet.
[70] M. Green,et al. EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.
[71] L. To,et al. High levels of circulating haemopoietic stem cells in very early remission from acute non‐lymphoblastic leukaemia and their collection and cryopreservation , 1984, British journal of haematology.